Circulating MicroRNAs as Quantitative Biomarkers for Diagnosis and Prognosis of Uveal Melanoma

Wen‐Da Zhou, Lei Shao, Li Dong, Ruiheng Zhang, Yifan Li, Heyan Li, Haotian Wu, Xu‐Han Shi, Wenbin WeiFrontiers in Oncology 2022 · DOI

This study, published in Frontiers in Oncology, explores the potential of serum microRNAs (miRNAs) as non-invasive "liquid biopsy" tools for uveal melanoma. By analyzing specific miRNA signatures, researchers identified miR-199a-3p as a highly accurate diagnostic marker and miR-21-5p as a powerful prognostic indicator for identifying aggressive tumor types and metastatic progression.

TL;DR

Researchers have identified specific circulating microRNAs in the blood that can accurately diagnose uveal melanoma and predict its metastatic potential. This "liquid biopsy" approach offers a non-invasive, quantitative alternative to traditional imaging and risky tissue biopsies, potentially enabling earlier detection and better patient monitoring.

What Problem Does This Paper Address?

Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. While it starts in the eye, it is highly aggressive; nearly half of patients eventually develop metastatic disease, which is often fatal.

Currently, doctors rely on imaging techniques like ultrasound, MRI, and slit-lamp examinations for diagnosis. However, these methods are qualitative and subjective, making early-stage diagnosis difficult. Furthermore, determining a patient’s prognosis—specifically whether the tumor is composed of less aggressive "spindle" cells or highly aggressive "epithelioid" cells—usually requires an invasive needle biopsy of the eye. These biopsies carry risks like hemorrhage or tumor seeding. There is a critical need for a non-invasive, quantitative biomarker that can both diagnose UM and predict its behavior.

Methods

The researchers focused on circulating microRNAs (miRNAs)—small RNA molecules that regulate gene expression and are stable enough to be detected in the blood.

  1. Candidate Selection: Based on previous literature and microarray data, the team selected six candidate miRNAs: miR-132-3p, miR-21-5p, miR-34a-5p, miR-126-3p, miR-199a-3p, and miR-214-3p.
  2. Cohort Validation: They tested these candidates in a cohort of 20 patients with localized UM (10 spindle-shaped, 10 epithelioid) and 10 healthy controls. An additional 5 patients with metastatic UM were used to verify performance in advanced disease.
  3. Quantification: Serum levels were measured using quantitative real-time PCR (qRT-PCR), the gold standard for sensitive RNA detection.
  4. Statistical Analysis: The team used Receiver Operating Characteristic (ROC) curves to calculate the Area Under the Curve (AUC), a metric where 1.0 represents a perfect diagnostic test.

Datasets

The study utilized a primary clinical dataset collected at the Beijing Tongren Hospital between 2013 and 2020:

  • Localized UM Group: 20 patients (split evenly between spindle and epithelioid cell types).
  • Healthy Control Group: 10 donors with no history of tumors.
  • Metastatic Verification Set: 5 patients with confirmed metastatic UM (primarily to the liver and bone).

Key Insights and Ideas

  • The Diagnostic "Star": miR-199a-3p emerged as the most effective diagnostic marker. It was significantly elevated in UM patients compared to healthy controls, regardless of the tumor's specific cell type.
  • The Prognostic "Star": miR-21-5p proved exceptional at distinguishing between tumor subtypes. It was significantly higher in the aggressive epithelioid cell type than in the spindle-shaped type.
  • Liquid Biopsy vs. Tissue Biopsy: The study demonstrates that serum miRNA levels mirror the molecular profile of the actual tumor tissue. This suggests we can "read" the tumor's aggressiveness through a simple blood draw rather than an intraocular biopsy.
  • Metastatic Tracking: Both miR-199a-3p and miR-21-5p remained elevated or increased further in metastatic cases, suggesting they could be used to monitor patients for recurrence or spread after their initial treatment.

Key Results

  • Diagnostic Accuracy: miR-199a-3p achieved an AUC of 0.985, with a sensitivity of 95% and specificity of 100% for detecting UM.
  • Subtype Differentiation: miR-21-5p distinguished epithelioid cells from spindle cells with an AUC of 0.980 (100% sensitivity, 90% specificity).
  • Metastatic Significance: miR-21-5p levels were significantly higher ($p < 0.001$) in metastatic patients compared to those with localized, lower-risk spindle tumors.
  • Downregulation Trends: Interestingly, miR-132-3p was significantly downregulated in aggressive epithelioid patients compared to spindle-cell patients, providing a secondary confirmatory marker.

Limitations and Future Work

While promising, the authors acknowledge several hurdles:

  • Small Sample Size: With only 35 total participants, the study is a "preliminary" validation. Larger, multi-center trials are needed to ensure these markers work across diverse populations.
  • Biological Mechanism: The study identifies that these miRNAs change, but not exactly why or how they are secreted into the bloodstream. Understanding the underlying signaling pathways (like the role of miR-21-5p as an oncogene) is a necessary next step.
  • Longitudinal Monitoring: Future studies should track miRNA levels in the same patients over several years to see if a spike in miR-21-5p can predict metastasis before it shows up on an MRI.

Summary updated

Abstract

For uveal melanoma (UM) patients, it is significant to establish diagnosis and prognosis evaluation systems through imaging techniques. However, imaging examinations are short of quantitative biomarkers and it is difficult to finish early diagnosis of UM. In order to discover new molecular biomarkers for the diagnosis and prognostic evaluation of UM, six circulating miRNAs (mir-132-3p, mir-21-5p, mir-34a-5p, mir-126-3p, mir-199a-3p, mir-214-3p) were chosen as candidates for independent validation. Validation of these miRNAs was performed in a cohort of 20 patients, including 10 spindle-shaped melanoma and 10 epithelioid cell melanoma, and 10 healthy donors. Then 5 patients with metastatic UM were included to validate the performance of miRNAs in advanced UM. Serum levels of miRNAs were determined using quantitative real-time PCR. We confirmed significantly higher levels of three miRNAs in serum of UM patients in comparison to healthy controls, and miR-199a-3p had the best performance (<i>p</i> < 0.0001; AUC = 0.985). MiR-214-3p and miR-21-5p were significantly upregulated in serum of epithelioid cell melanoma patients compared to spindle-shaped melanoma patients and miR-132-3p and, conversely, were significantly downregulated in serum of epithelioid cell melanoma patients. MiR-21-5p shows their best performance (<i>p</i> < 0.0001; AUC = 0.980). Both miR-199a-3p and miR-21-5p showed great performance in advanced UM. Significantly higher levels of miR-21-5p (<i>p</i> < 0.001) were found in serum of metastatic UM patients compared to patients with localized spindle-shaped melanoma, and significantly higher levels of miR-199a-3p (<i>p</i> < 0.001) were detected in serum of metastatic UM patients compared to healthy controls. Our preliminary data indicate promising diagnostic utility of circulating miR-199a-3p and promising prognostic utility of circulating miR-21-5p in both early and advanced UM patients.
BibTeX
@inproceedings{zhou2022circulating,
  author = {Wen‐Da Zhou and Lei Shao and Li Dong and Ruiheng Zhang and Yifan Li and Heyan Li and Haotian Wu and Xu‐Han Shi and Wenbin Wei},
  title = {{Circulating MicroRNAs as Quantitative Biomarkers for Diagnosis and Prognosis of Uveal Melanoma}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.854253},
}
Figure